SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$2.43 USD
+0.05 (2.10%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $2.44 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
SCYNEXIS, Inc. [SCYX]
Reports for Purchase
Showing records 41 - 60 ( 66 total )
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Developing a New Class of Antifungal -Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: LEBOYER R
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
We are placing shares of SCYX Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
As Antifungal Pipeline Progresses, C. Auris Trial Kicks Off
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Just Like the White Winged DOVE...SCYNEXIS Is Dosing in VVC
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Addressing SCY-078 IV Clinical Hold, as Oral SCY-078s Ph2b in VVC Begins
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
We initiate with a Buy rating and $8.50 price target
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
IV ''078 Receives FDA Feedback it Needs But Perhaps Not the Kind it Deserves
Provider: H.C. Wainwright & Co., Inc.
Analyst: DAVIS C